MD Anderson Cancer Center
In October 2015, OncoResponse announced a broad strategic alliance with MD Anderson Cancer Center. As part of this alliance, MD Anderson will provide access to samples and physiologic, prognostic and genotypic data from patients that have responded well to cancer immunotherapies, along with oncology and translational medicine expertise.
At the founding in October 2015, OncoResponse licensed Theraclone’s proven immune repertoire screening technology for the identification of therapeutic antibodies against novel targets from immuno-oncology treated patients. The technology rapidly identifies antibodies made by the human immune system with exceptional reactivity to targets on myeloid cells to relieve immunosuppression in the tumor microenvironment.